U.S. Patent Trial and Appeal Board (PTAB)

Gilead Versus HHS: Gilead Loses 2nd Patent Invalidation Challenge

Business, Department of Health and Human Services (HHS), Lawsuits, Patent Challenges, Trump Administration, U.S. Centers for Disease Control and Prevention, U.S. Patent Trial and Appeal Board (PTAB)

Gilead Sciences lost yet another challenge to the company’s U.S. patent to Truvada for HIV prevention, or PrEP.

Multiple Sclerosis Update: Biogen, Sanofi, Active, Adamas and Novartis

Blockbusters, Bruton's Tyrosine Kinase (BTK) Inhibitors, Business, Clinical Trial Endpoints, Clinical Trials, CNS damage, MS with walking impairment, Multiple Sclerosis, Neurology, Patent Challenges, R&D, Secondary Endpoints, Shares, U.S. Patent Trial and Appeal Board (PTAB)

Biogen successfully fended off a patent challenge from generic company Mylan over the multiple sclerosis (MS) drug Tecfidera.

Allergan ruling casts doubt on tribal patent strategy

Blockbusters, Dry Eye Disease, Generics, Legal, Native American tribes, Patents, U.S. Patent Trial and Appeal Board (PTAB)

A U.S. judge’s ruling invalidating Allergan Plc’s patents on its blockbuster $1.5 billion dry-eye medicine Restasis has cast doubt on the company’s novel strategy to enlist a Native American tribe to help shield those patents from challenge by generic drugmakers, legal experts said.